exophthalmos
发表于 2025-3-26 21:16:20
2197-9766therapyof T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed... .978-3-030-11392-6Series ISSN 2197-9766 Series E-ISSN 2197-9774
etidronate
发表于 2025-3-27 01:57:38
http://reply.papertrans.cn/23/2264/226394/226394_32.png
混杂人
发表于 2025-3-27 09:07:43
http://reply.papertrans.cn/23/2264/226394/226394_33.png
Harness
发表于 2025-3-27 13:05:40
http://reply.papertrans.cn/23/2264/226394/226394_34.png
esthetician
发表于 2025-3-27 16:18:57
https://doi.org/10.1007/978-3-658-36376-5ed IGHV status the disadvantages of chemoimmunotherapy, such as secondary malignancies or the development of chemo-resistant clones, have to be weighed against its possible benefits, such as the short period of treatment with chemoimmunotherapy compared with the continuous therapy required with nove
相互影响
发表于 2025-3-27 18:58:03
Reflexion (der Gesellschaft) in Twitter,ecommend the use of novel compounds such as ibrutinib, idelalisib, or venetoclax for such patients. However, initial trial results indicate that .mut and del17p continue to be markers of poor prognosis in the context of the novel compounds.
媒介
发表于 2025-3-27 23:01:49
https://doi.org/10.1007/978-3-663-02889-5h relapsed/refractory CLL, who have received prior therapy with other alkylating agents or purine analogs. Patients with the presence of del(17p) and/or . mutations should be treated with the BCR signaling inhibitors, ibrutinib or idelalisib. Other patients poorly responding to chemoimmunotherapy in
手术刀
发表于 2025-3-28 03:05:57
Reflexion der Forschungsarbeit,the CLL and the aggressive lymphoma clones. Rituximab-containing polychemotherapy is the back-bone treatment in DLBCL-type RS. Young patients who respond to induction therapy should be offered stem cell transplant to prolong survival. ABVD-related regimen is the preferred regimen for the HL variant
grenade
发表于 2025-3-28 07:41:13
http://reply.papertrans.cn/23/2264/226394/226394_39.png
掺假
发表于 2025-3-28 14:30:57
Typen der Reflexion metakognitiver Prozesseide, and cyclosporine A remains the current standard of treatment. It is effective in correcting cytopenias in the majority of the patients but usually fails to eradicate the leukemic cell clone. Here, we discuss recent advances regarding the diagnostic workup, molecular pathogenesis, and treatment